Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$97.16
+1.0%		$94.65
$44.42
▼
$151.02
$4.75B0.191.08 million shs227,253 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$59.81
+1.3%		$55.27
$14.78
▼
$62.32
$4.38B0.31.23 million shs314,715 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$13.19
+0.6%		$11.01
$7.36
▼
$13.90
$1.17B0.441.65 million shs396,744 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$18.72
+1.1%		$19.32
$3.86
▼
$21.27
$4.10B1.693.14 million shs281,850 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+4.59%+1.18%+9.67%+4.03%+79.54%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+1.99%-3.06%+1.67%+66.27%+182.48%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+1.71%+0.38%+42.66%+49.49%+64.91%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+0.11%-4.88%-1.44%+27.30%+405.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$97.16
+1.0%		$94.65
$44.42
▼
$151.02
$4.75B0.191.08 million shs227,253 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$59.81
+1.3%		$55.27
$14.78
▼
$62.32
$4.38B0.31.23 million shs314,715 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$13.19
+0.6%		$11.01
$7.36
▼
$13.90
$1.17B0.441.65 million shs396,744 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$18.72
+1.1%		$19.32
$3.86
▼
$21.27
$4.10B1.693.14 million shs281,850 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+4.59%+1.18%+9.67%+4.03%+79.54%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+1.99%-3.06%+1.67%+66.27%+182.48%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+1.71%+0.38%+42.66%+49.49%+64.91%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+0.11%-4.88%-1.44%+27.30%+405.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
2.82
Moderate Buy$154.5560.65% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.78
Moderate Buy$75.0027.10% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.69
Moderate Buy$25.4093.75% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.93
Moderate Buy$25.9240.01% Upside

Current Analyst Ratings Breakdown

Latest KURA, CELC, ELVN, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$24.00
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$24.00
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$24.00
8/20/2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/20/2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$28.00 ➝ $29.00
8/18/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/18/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$78.00
8/18/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$62.00 ➝ $73.00
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$165.00 ➝ $175.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A($0.26) per shareN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$12.22 per shareN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M17.28N/AN/A$0.54 per share24.28
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$15.35M264.25N/AN/A$4.06 per share4.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.67N/AN/AN/AN/A-18.55%-18.09%11/11/2026 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.37N/AN/AN/A-384.30%-207.18%-45.17%11/3/2026 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$276.48M-$1.57N/AN/AN/AN/A-42.27%-38.67%11/5/2026 (Estimated)

Latest KURA, CELC, ELVN, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/6/2026Q2 2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.3911-$0.41-$0.0189-$0.41$0.96 million$0.35 million
8/5/2026Q2 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.3872-$0.49-$0.1028-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
64.07
64.07
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.12
4.73
4.71
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.27
18.27

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
5.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4048.93 million42.41 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5073.27 million71.07 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13088.96 million82.20 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330219.14 million208.10 millionOptionable

Recent News About These Companies

Bank of New York Mellon Corp Acquires New Shares in Relay Therapeutics, Inc. $RLAY
September 3 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-acquires-new-shares-in-relay-therapeutics-inc-rlay-2026-09-03/
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts
September 3 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000065
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages
September 3 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-relay-therapeutics-inc-nasdaq-rlay-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-09-03/
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
September 2 at 2:00 PM  |  fool.comhttps://www.fool.com/coverage/filings/2026/09/02/relay-therapeutics-cfo-sells-17717-shares-for-350000/
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats
September 1 at 4:50 PM  |  quiverquant.comQ
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 1 at 4:46 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354648/0/en/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-september.html
263,506 Shares in Relay Therapeutics, Inc. $RLAY Acquired by The Manufacturers Life Insurance Company
September 1 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-263506-shares-in-relay-therapeutics-inc-rlay-acquired-by-the-manufacturers-life-insurance-company-2026-09-01/
Moore Capital Management LP Purchases Shares of 414,005 Relay Therapeutics, Inc. $RLAY
August 31 at 6:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moore-capital-management-lp-purchases-shares-of-414005-relay-therapeutics-inc-rlay-2026-08-31/
Relay Therapeutics (NASDAQ:RLAY) Major Shareholder Sells $116,400,000.00 in Stock
August 31 at 4:08 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30994721
Peter Rahmer Sells 4,508 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock
August 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rlay-insider-buying-and-selling-2026-08-29/
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 4,508 Shares of Stock
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-relay-therapeutics-nasdaq-rlay-insider-sells-4508-shares-of-stock-2026-08-28/
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each
August 28, 2026  |  kalkinemedia.comK
Relay Therapeutics (NASDAQ:RLAY) Major Shareholder Sells 6,000,000 Shares
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-relay-therapeutics-nasdaq-rlay-major-shareholder-sells-6000000-shares-2026-08-28/
J. Goldman & Co LP Takes Position in Relay Therapeutics, Inc. $RLAY
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-j-goldman-co-lp-takes-position-in-relay-therapeutics-inc-rlay-2026-08-27/
Sanctuary Advisors LLC Makes New $2 Million Investment in Relay Therapeutics, Inc. $RLAY
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sanctuary-advisors-llc-makes-new-2-million-investment-in-relay-therapeutics-inc-rlay-2026-08-27/
Deutsche Bank AG Invests $3.07 Million in Relay Therapeutics, Inc. $RLAY
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-invests-307-million-in-relay-therapeutics-inc-rlay-2026-08-27/
15,288,202 Shares in Relay Therapeutics, Inc. $RLAY Bought by BlackRock Inc.
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-15288202-shares-in-relay-therapeutics-inc-rlay-bought-by-blackrock-inc-2026-08-27/
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% - Should You Sell?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-relay-therapeutics-nasdaq-rlay-trading-down-48-should-you-sell-2026-08-26/
Ieq Capital LLC Takes Position in Relay Therapeutics, Inc. $RLAY
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ieq-capital-llc-takes-position-in-relay-therapeutics-inc-rlay-2026-08-26/
Elmind Capital LP Makes New $27.42 Billion Investment in Relay Therapeutics, Inc. $RLAY
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-elmind-capital-lp-makes-new-2742-billion-investment-in-relay-therapeutics-inc-rlay-2026-08-26/
Connor Clark & Lunn Investment Management Ltd. Acquires Shares of 961,702 Relay Therapeutics, Inc. $RLAY
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-acquires-shares-of-961702-relay-therapeutics-inc-rlay-2026-08-26/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$97.16 +0.96 (+0.99%)
As of 11:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$59.80 +0.80 (+1.35%)
As of 11:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$13.19 +0.08 (+0.64%)
As of 11:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$18.72 +0.21 (+1.13%)
As of 11:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas